These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
697 related articles for article (PubMed ID: 33141149)
41. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486 [TBL] [Abstract][Full Text] [Related]
42. Initial Glycemic Control and Care Among Younger Adults Diagnosed With Type 2 Diabetes. Gopalan A; Mishra P; Alexeeff SE; Blatchins MA; Kim E; Man A; Karter AJ; Grant RW Diabetes Care; 2020 May; 43(5):975-981. PubMed ID: 32132007 [TBL] [Abstract][Full Text] [Related]
43. Diabetes, use of metformin, and the risk of meningioma. Seliger C; Meier CR; Becker C; Jick SS; Proescholdt M; Bogdahn U; Hau P; Leitzmann MF PLoS One; 2017; 12(7):e0181089. PubMed ID: 28708856 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of effectiveness of treatment paradigm for newly diagnosed type 2 diabetes patients in Chin: A nationwide prospective cohort study. Cai X; Hu D; Pan C; Li G; Lu J; Ji Q; Su B; Tian H; Qu S; Weng J; Zhang D; Xu J; Ji L J Diabetes Investig; 2020 Jan; 11(1):151-161. PubMed ID: 31161658 [TBL] [Abstract][Full Text] [Related]
45. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H Diabetes Care; 1999 Jan; 22(1):119-24. PubMed ID: 10333912 [TBL] [Abstract][Full Text] [Related]
46. Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study. Schmedt N; Andersohn F; Walker J; Garbe E Diabetes Obes Metab; 2019 Jan; 21(1):52-60. PubMed ID: 30047217 [TBL] [Abstract][Full Text] [Related]
47. Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017. Tan YZ; Cheen MHH; Goh SY; Bee YM; Lim PS; Khee GY; Thumboo J J Diabetes; 2019 Jul; 11(7):573-581. PubMed ID: 30556375 [TBL] [Abstract][Full Text] [Related]
48. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations. Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763 [TBL] [Abstract][Full Text] [Related]
49. Results of the Adequacy of glycemiC Control in pAtients with type 2 Diabetes mEllitus treated with Metformin monotherapY at the maximal-tolerated dose (ACCADEMY) study. Giorda CB; Cercone S; Nada E; Endocrine; 2016 Jun; 52(3):507-15. PubMed ID: 26275456 [TBL] [Abstract][Full Text] [Related]
50. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Bazelier MT; Gallagher AM; van Staa TP; Cooper C; Leufkens HG; Vestergaard P; de Vries F Pharmacoepidemiol Drug Saf; 2012 May; 21(5):507-14. PubMed ID: 22392882 [TBL] [Abstract][Full Text] [Related]
51. Correlation of long-term glycemic control as measured by glycated hemoglobin with serum angiopoietin-like 6 protein levels in type 2 diabetes mellitus patients. Sharma V; Pangtey GS; Gupta R; Rehan HS; Gupta LK Indian J Pharmacol; 2017; 49(3):250-253. PubMed ID: 29033485 [TBL] [Abstract][Full Text] [Related]
52. Prevalence of and factors associated with suboptimal glycemic control among patients with type 2 diabetes mellitus attending public hospitals in the Greater Male' Region, Maldives: a hospital-based cross-sectional study. Shareef J; Apidechkul T; Srichan P BMC Public Health; 2024 Apr; 24(1):1166. PubMed ID: 38664794 [TBL] [Abstract][Full Text] [Related]
53. Real world management of pregestational diabetes not achieving glycemic control for many patients in the UK. Cea-Soriano L; García-Rodríguez LA; Brodovicz KG; Masso-Gonzalez E; Bartels DB; Hernández-Díaz S Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):940-948. PubMed ID: 29740916 [TBL] [Abstract][Full Text] [Related]
54. Slow response to loss of glycemic control in type 2 diabetes mellitus. Brown JB; Nichols GA Am J Manag Care; 2003 Mar; 9(3):213-7. PubMed ID: 12643338 [TBL] [Abstract][Full Text] [Related]
55. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea. Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133 [TBL] [Abstract][Full Text] [Related]
56. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395 [TBL] [Abstract][Full Text] [Related]
57. Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. Huri HZ; Ling DY; Ahmad WA Drug Des Devel Ther; 2015; 9():4735-49. PubMed ID: 26316711 [TBL] [Abstract][Full Text] [Related]
58. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
59. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965 [TBL] [Abstract][Full Text] [Related]
60. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction. Lin SN; Phang KK; Toh SH; Chee KH; Zaman Huri H Front Endocrinol (Lausanne); 2020; 11():448. PubMed ID: 32754118 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]